Minovia Therapeutics

New Capabilities

As of May 2026: Clinical-stage mitochondrial transplantation company

For most of modern medicine's history, diseases caused by defective mitochondria (the structures inside cells that generate energy) have been essentially untreatable. Doctors could manage symptoms, but the broken power plants themselves were beyond reach. In six months, the FDA approved the first two drugs for mitochondrial diseases, and a Chinese research team showed a new transplant method that's sixteen times more efficient than previous approaches.

Updated May 30